(Q41689996)

English

The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines

scientific article published on September 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Milton Weinstein

8

object named as

Weinstein MC

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Anna N. A. Tosteson

5

object named as

Tosteson AN

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

author name string

Goldman L

1

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Coxson P

2

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Hunink MG

3

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Goldman PA

4

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Mittleman M

6

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Williams L

7

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

language of work or name

0 references

publication date

1 September 1999

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Journal of the American College of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

768-776

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost and health implications of cholesterol lowering

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The cost effectiveness of lipid lowering in Swedish primary health care. The CELL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of Coronary Heart Disease Using Risk Factor Categories

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cholesterol reduction yields clinical benefit: impact of statin trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of the Conference on Low Blood Cholesterol: Mortality Associations

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention and Medicare costs

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Health policy on blood cholesterol. Time to change directions

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. American College of Physicians. Part 1

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Variations in cholesterol management practices of U.S. physicians.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Current status of cholesterol treatment in the community: the Minnesota Heart Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Relative impact of targeted versus populationwide cholesterol interventions on the incidence of coronary heart disease. Projections of the Coronary Heart Disease Policy Model

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Trends in serum cholesterol levels from 1980 to 1987. The Minnesota Heart Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. A statement from the National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Indications for cholesterol-lowering medication: comparison of risk-assessment methods

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900260-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0735-1097(99)00260-0

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41689996&oldid=1925929260"